Search results
Showing 151 to 165 of 215 results for arthritis
We have moved interventional procedures guidance 663 to become HealthTech guidance 529. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE guideline NG100.
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Discontinued Reference number: GID-TA11244
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
This appraisal has been updated and replaced by NICE technology appraisal guidance 195.
This guidance has been updated and replaced by NICE technology appraisal guidance 199.
This guidance has been updated and replaced by NICE technology appraisal guidance 195.
Tocilizumab for the treatment of rheumatoid arthritis (TA198)
This guidance has been updated and replaced by NICE technology appraisal guidance 247.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Agenda and papers of the NICE public board meeting on 19 January 2022
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.
This guidance has been updated and replaced by NICE technology appraisal guidance 340.